INSIGHTS
Pioneering Healing Research
We don't just practice ibogaine therapy—we advance the science behind it. Our research bridges ancient wisdom with modern neuroscience, contributing clinical evidence that's expanding what medicine believes is possible.
OUR RESEARCH MISSION
The Iboga Wellness Institute bridges ancestral wisdom with modern science. Honoring iboga's ceremonial legacy, we pursue research that validates therapeutic applications, enhances safety protocols, explores new treatment populations, respects indigenous knowledge, and advances global understanding of ibogaine's healing potential.
Groundbreaking Research Shaping the Field
The Iboga Wellness Institute draws upon and contributes to a rapidly expanding body of peer-reviewed scientific literature. Below are landmark studies that inform our evidence-based approach to ibogaine therapy.
Breakthrough Studies from Leading Universities
STANFORD UNIVERSITY
Magnesium-Ibogaine Therapy in Veterans with Traumatic Brain Injuries, Nature Medicine, 2024
This landmark clinical trial evaluated 30 retired Navy SEALs with traumatic brain injury who demonstrated major improvements across a variety of psychometric symptoms, including disability, post-traumatic stress, depression and anxiety. The study helped spark a major upsurge in ibogaine research and even state-level funding initiatives in the U.S.
JOHN HOPKINS UNIVERSITY
Psychedelics Reopen Critical Periods for Social Learning Nature, 2023
Johns Hopkins researchers discovered that psychedelic drugs, including ibogaine, can reopen critical periods in the brain when mammals are more sensitive to learning from their environment. For ibogaine specifically, the critical period remained open for four weeks following a single dose—the longest duration among all psychedelics tested.
UNIVERSITY OF CALIFORNIA, DAVIS
Total Synthesis of Ibogaine Opens New Research Pathways Nature Chemistry, 2025
UC Davis researchers achieved the total synthesis of ibogaine and related compounds from inexpensive, widely available chemicals. This breakthrough enables efficient production of ibogaine analogues for research, potentially leading to safer, more targeted treatments.
YALE & UCSF COLLABORATION
Safer Ibogaine-Inspired Compounds for Addiction Cell, 2023
UC Davis researchers achieved the total synthesis of ibogaine and related compounds from inexpensive, widely available chemicals. This breakthrough enables efficient production of ibogaine analogues for research, potentially leading to safer, more targeted treatments.
Pioneering Research on Neurological Applications
AMBIO LIFE SCIENCES & CANADIAN RESEARCHERS, 2025
Frontiers in Immunology: Ibogaine Treatment for Multiple Sclerosis
This groundbreaking case report documented two MS patients who showed remarkable neuroimaging changes and clinical improvements following ibogaine treatment. One patient demonstrated a 71% reduction in the volume of white matter lesions post-treatment.
Findings:
- Substantial lesion shrinkage suggesting remyelination
- Decreased inflammation markers in brain tissue
- Improvements in motor function and cognitive processing
- Changes in cortical and subcortical brain regions
UNIVERSITY OF THE WITWATERSRAND & UNIVERSITY OF CAPE TOWN, 2024
Frontiers in Neuroscience: Ibogaine Upregulates Myelination Markers
Preclinical research demonstrated that ibogaine upregulates genes and proteins involved in remyelination, highlighting an important mechanism for brain injury repair and treatment of substance use disorders. This research has implications for multiple sclerosis, stroke, and other myelin-associated diseases.
Clinical Outcome Studies
JOHN HOPKINS MEDICINE
Subjective Effectiveness for Opioid Use Disorder, Journal of Psychedelic Studies, 2018
This study surveyed 88 patients who received ibogaine treatment, providing valuable long-term outcome data. Most participants (80%) reported that ibogaine eliminated or drastically reduced withdrawal symptoms, with 30% achieving complete abstinence from opioids.
Long-Term Outcomes:
- 50% reported ibogaine reduced opioid craving, with 25% reporting reduction lasting at least 3 months
- Nearly half of abstainers maintained abstinence for one year
- Strong spiritual experiences correlated with better outcomes
UNIVERSITY OF OTAGO
12-Month Follow-Up Observational Study, Journal of Psychopharmacology, 2017
This New Zealand study followed 14 patients after ibogaine treatment for opioid dependence over 12 months. The legal status of ibogaine in New Zealand provided a unique opportunity to evaluate durability of treatment outcomes in a medically supervised setting.
UNIVERSITY OF BASEL
Systematic Literature Review of Clinical Trials, Journal of Substance Abuse Treatment, 2022
This comprehensive systematic review analyzed 24 studies involving 705 participants. Data suggest ibogaine is an effective therapeutic intervention for substance use disorders, reducing withdrawal symptoms and craving, while also showing beneficial impact on depressive and trauma-related symptoms.
Conclusions:
- Rapid-onset therapy offers novel treatment opportunities
- Rigorous study designs within medical settings necessary for safe application
- Need for continued research on safety protocols
State & Federal Research Initiatives
The therapeutic potential of ibogaine has captured the attention of government agencies and state legislatures, leading to unprecedented funding for research:
TEXAS IBOGAINE RESEARCH INITIATIVE (2025)
The state of Texas allocated $50 million to fund clinical research on ibogaine, aiming to develop an FDA-approved treatment for opioid use disorder and other conditions. This initiative established a consortium of universities, hospitals, and drug developers, positioning Texas as a leading center for psychedelic medicine research.
KENTUCKY OPIOID ABATEMENT ADVISORY COMMISSION
Kentucky considered allocating $42 million from opioid lawsuit settlements to study ibogaine therapy, marking the first time a U.S. state explored funding research into this approach. The move underscores the urgent need to expand treatment options for the opioid epidemic.
NATIONAL INSTITUTES OF HEALTH (NIH)
After a decades-long hiatus, the NIH has begun awarding grants for psychedelic research, including studies on ibogaine analogues and related compounds. This represents the first significant federal funding for psychedelic therapeutic research in over half a century.
NATIONAL INSTITUTE ON DRUG ABUSE (NIDA)
NIDA is actively working with pharmaceutical startups to investigate how ibogaine and its analogues might be used to treat drug dependency, focusing on developing safer, non-hallucinogenic versions that retain therapeutic efficacy.
CLINICAL EVIDENCE
The Neuroscience of Recovery
From addiction recovery to neurological regeneration, ibogaine research spans multiple therapeutic frontiers. Here's how the scientific community is unlocking ibogaine's potential across diverse medical applications—each backed by rigorous clinical evidence and groundbreaking discoveries.
Addiction & Dependency
Our research documents ibogaine's ability to eliminate opioid withdrawal and reduce cravings within 24-36 hours, with successful outcomes for alcohol use disorder, stimulant addiction, and long-term abstinence in patients who've failed conventional treatment.
Mental Health & Trauma
Studies show 88% PTSD symptom reduction one month post-treatment, alongside remarkable outcomes for treatment-resistant depression and anxiety. Ibogaine enhances neuroplasticity in trauma-affected brain regions, creating a therapeutic window conventional treatment cannot access.
Neurological Conditions
Our research examines ibogaine's ability to stimulate GDNF production for Parkinson's disease, reduce neuroinflammation in brain injury, explore remyelination potential in MS, and document cognitive recovery including improved memory and executive function in TBI patients.
